This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Downie, D. Articles by Murray, G. I. Search for Related Content PubMed PubMed Citation Articles by Downie, D. Articles by Murray, G. I.

Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers

Authors' Affiliations: ¹ Department of Pathology, University of Aberdeen; ² Department of Gynaecologic Oncology, Aberdeen Royal Infirmary; and ³ Auvation, Ltd., Aberdeen, United Kingdom

Requests for reprints: Graeme I. Murray, Department of Pathology, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom. Phone: 44-1224-553794/554785; Fax: 44-1224-663002; E-mail: g.i.murray{at}abdn.ac.uk.

Purpose: The cytochromes P450 are a multigene family of enzymes with a central role in the oxidative metabolism of a wide range of xenobiotics, including anticancer drugs and biologically active endogenous compounds. The purpose of this study was to define the cytochrome P450 profile of ovarian cancer and identify novel therapeutic targets and establish the prognostic significance of expression of individual cytochrome P450s in this type of cancer.

Experimental Design: Immunohistochemistry for a panel of 23 cytochrome P450s and cytochrome P450 reductase was done on an ovarian cancer tissue microarray consisting of 99 primary epithelial ovarian cancers, 22 peritoneal metastasis, and 13 normal ovarian samples. The intensity of immunoreactivity in each sample was established by light microscopy.

Results: In primary ovarian cancer, several P450s (CYP1B1, CYP2A/2B, CYP2F1, CYP2R1, CYP2U1, CYP3A5, CYP3A7, CYP3A43, CYP4Z1, CYP26A1, and CYP51) were present at a significantly higher level of intensity compared with normal ovary. P450 expression was also detected in ovarian cancer metastasis and CYP2S1 and P450 reductase both showed significantly increased expression in metastasis compared with primary ovarian cancer. The presence of low/negative CYP2A/2B (log rank = 7.06, P = 0.008) or positive CYP4Z1 (log rank = 6.19, P = 0.01) immunoreactivity in primary ovarian cancer were each associated with poor prognosis. Both CYP2A/2B and CYP4Z1 were also independent markers of prognosis.

Conclusions: The expression profile of individual P450s has been established in ovarian cancer. Several P450s show increased expression in ovarian cancer and this provides the basis for developing P450-based therapeutics in ovarian cancer. Expression of CYP2A/2B or CYP4Z1 in primary ovarian cancer were independent markers of prognosis.

This article has been cited by other articles:

				W. R. Ware Nutrition and the Prevention and Treatment of Cancer: Association of Cytochrome P450 CYP1B1 With the Role of Fruit and Fruit Extracts Integr Cancer Ther, March 1, 2009; 8(1): 22 - 28. [Abstract] [PDF]

				C. Rodriguez-Antona, S. Leskela, M. Zajac, M. Cuadros, J. Alves, M. V. Moneo, C. Martin, J. C. Cigudosa, A. Carnero, M. Robledo, et al. Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas Blood, November 1, 2007; 110(9): 3345 - 3351. [Abstract] [Full Text] [PDF]

				J. A. Barnett, D. L. Urbauer, G. I. Murray, G. N. Fuller, and A. B. Heimberger Cytochrome P450 1B1 Expression in Glial Cell Tumors: An Immunotherapeutic Target Clin. Cancer Res., June 15, 2007; 13(12): 3559 - 3567. [Abstract] [Full Text] [PDF]

				S. Ekins, D. C. Mankowski, D. J. Hoover, M. P. Lawton, J. L. Treadway, and H. J. Harwood Jr. Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Human CYP51 Inhibitors Drug Metab. Dispos., March 1, 2007; 35(3): 493 - 500. [Abstract] [Full Text] [PDF]

				L.-R. Zhu, P. E. Thomas, G. Lu, K. R. Reuhl, G.-Y. Yang, L.-D. Wang, S.-L. Wang, C. S. Yang, X.-Y. He, and J.-Y. Hong CYP2A13 in Human Respiratory Tissues and Lung Cancers: An Immunohistochemical Study with A New Peptide-Specific Antibody Drug Metab. Dispos., October 1, 2006; 34(10): 1672 - 1676. [Abstract] [Full Text] [PDF]

				D. N. Shelton, I. T. Sandoval, A. Eisinger, S. Chidester, A. Ratnayake, C. M. Ireland, and D. A. Jones Up-regulation of CYP26A1 in Adenomatous Polyposis Coli-Deficient Vertebrates via a WNT-Dependent Mechanism: Implications for Intestinal Cell Differentiation and Colon Tumor Development. Cancer Res., August 1, 2006; 66(15): 7571 - 7577. [Abstract] [Full Text] [PDF]

				Z.-L. Wu, C. D. Sohl, T. Shimada, and F. P. Guengerich Recombinant Enzymes Overexpressed in Bacteria Show Broad Catalytic Specificity of Human Cytochrome P450 2W1 and Limited Activity of Human Cytochrome P450 2S1 Mol. Pharmacol., June 1, 2006; 69(6): 2007 - 2014. [Abstract] [Full Text] [PDF]